The PI3K/Akt/mTOR pathway in ovarian cancer： therapeutic opportunities and challenges
The PI3K/Akt/mTOR pathway in ovarian cancer： therapeutic opportunities and challenges
About this item
Full title
Author / Creator
Publisher
London: BioMed Central
Journal title
Language
English
Formats
Publication information
Publisher
London: BioMed Central
Subjects
More information
Scope and Contents
Contents
The phosphatidylinositol 3 kinase （PI3K） pathway is frequently altered in cancer, including ovarian cancer （OC）. Unfortunately, despite a sound biological rationale and encouraging activity in preclinical models, trials of first-generation inhibitors of mammalian target of rapamycin （mTOR） in OC have demonstrated negative results. The lack of patie...
Alternative Titles
Full title
The PI3K/Akt/mTOR pathway in ovarian cancer： therapeutic opportunities and challenges
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_wiley_primary_10_5732_cjc_014_10289_CAC2CJC01410289
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_wiley_primary_10_5732_cjc_014_10289_CAC2CJC01410289
Other Identifiers
ISSN
1000-467X,2523-3548
E-ISSN
1944-446X,2523-3548
DOI
10.5732/cjc.014.10289
